Company Profile
InventisBio Co., Limited, a clinical stage biotech company focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications.
Its portfolio also includes Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer, and Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer. It also develops Dย2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease
Darbinurad (D-0120), which is in phase II clinical trial to treat gout. Additionally, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors. Its portfolio also includes YF550 which is in preclinical trial to treat chromosome instability solid tumors, and YF057 which is in preclinical trial to treat atopic dermatitis and asthma. Founded in 2013, InventisBio Co. is based in Shanghai, China.